[Vogt-Koyanagi-Harada syndrome in the setting of vemurafenib therapy for metastatic melanoma: a case report].

Abstract

A 53-year-old female patient complained of 1 week of bilateral visual blurring. She was previously diagnosed with metastatic melanoma of the inguinal lymph nodes and treated with the oral targeted drug vemurafenib. She exhibited aqueous flare in the left eye, and her fundus examination revealed optic disc swelling in the left eye and bilateral serious detachment of the retinal neuroepithelial layer. Fluorescein angiography showed multiple pinpoint hyperfluorescence leakage spots in the prometaphase and appeared as multilobular dye pooling in the late phase. We diagnosed her as Vogt-Koyanagi-Harada syndrome and gave glucocorticoid treatment for eyes. Oral vemurafenib was also taken intermittently under the guidance of an oncologist. After treatment, her bilateral vision improved, the anterior segment inflammation disappeared, and the retinal neuroepithelial layer reattached, with presence of the "sunset glow" fundus.

• Authors: X T Ren, T Guo, F Yang, W Y Wu, H L Dou, X M Li
• Journal: [Zhonghua yan ke za zhi] Chinese journal of ophthalmology (Zhonghua Yan Ke Za Zhi) Vol. 58 Issue 11 Pg. 925-928 (Nov 11 2022) ISSN: 0412-4081 [Print] China
• PMID: 36348532 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Vemurafenib

Topics

• Humans
• Female
• Middle Aged
• Uveomeningoencephalitic Syndrome (drug therapy)
• Vemurafenib (adverse effects)
• Fluorescein Angiography
• Melanoma (drug therapy)
• Fundus Oculi
• Vision Disorders (etiology)